NASDAQ:APLT Applied Therapeutics Q4 2024 Earnings Report $0.49 -0.02 (-3.64%) Closing price 04:00 PM EasternExtended Trading$0.48 -0.01 (-1.97%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Applied Therapeutics EPS ResultsActual EPS-$0.24Consensus EPS -$0.18Beat/MissMissed by -$0.06One Year Ago EPSN/AApplied Therapeutics Revenue ResultsActual Revenue$0.00 millionExpected Revenue$0.61 millionBeat/MissMissed by -$615.00 thousandYoY Revenue GrowthN/AApplied Therapeutics Announcement DetailsQuarterQ4 2024Date4/14/2025TimeBefore Market OpensConference Call DateMonday, April 14, 2025Conference Call Time9:30AM ETUpcoming EarningsApplied Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Monday, November 10, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Applied Therapeutics Earnings HeadlinesApplied Therapeutics Inc. (NASDAQ:APLT) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 27 at 2:29 AM | americanbankingnews.comQ3 Earnings Estimate for APLT Issued By Leerink PartnrsAugust 23, 2025 | americanbankingnews.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 29 at 2:00 AM | Brownstone Research (Ad)Applied Therapeutics Reports Q2 LossAugust 15, 2025 | theglobeandmail.comApplied Therapeutics reports Q2 EPS (15c), consensus (16c)August 14, 2025 | msn.comApplied Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comSee More Applied Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email. Email Address About Applied TherapeuticsApplied Therapeutics (NASDAQ:APLT), Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.View Applied Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures Upcoming Earnings Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Micron Technology (9/24/2025)Costco Wholesale (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.